SCHEMBL8800604

SCHEMBL8800604

O=Cc1ccc(OCc2cscn2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
KDM4E B2RXH2 4/20 0.56
L3MBTL1 Q9Y468 1/20 0.48
LMNA P02545 3/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
RAB9A P51151 2/20 0.44
LTA4H P09960 1/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
ALOX5 P09917 1/20 0.40
CYP2A6 P11509 1/20 0.39
SLC6A3 Q01959 1/20 0.37
MMP13 P45452 1/20 0.37
MMP14 P50281 1/20 0.37
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834177 0.78 MAOB (0.46) SMN1; SMN2L3MBTL1MEN1KMT2ARAB9A
SCHEMBL4088281 0.78 SLC6A3 (0.47) ALDH1A1SMN1; SMN2KDM4ELMNAKMT2A
SCHEMBL14139631 0.75 PTGS2 (0.44) ALOX5SLC6A3MMP13MMP14
SCHEMBL4825951 0.75 LMNA (0.61) LMNAMEN1KMT2ARAB9AMAPT
SCHEMBL5228979 0.75 LTA4H (0.38) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL1118117 0.74 ALOX5 (0.40) ALDH1A1SMN1; SMN2LMNARAB9ALTA4H
SCHEMBL711126 0.74 TSHR (0.42) ALDH1A1SMN1; SMN2KDM4ELMNAMEN1
SCHEMBL14530530 0.74 SMN1; SMN2 (0.52) ALDH1A1SMN1; SMN2KDM4EL3MBTL1LMNA
SCHEMBL1928819 0.73 ALOX5 (0.47) ALDH1A1SMN1; SMN2RAB9ALTA4HALOX5
SCHEMBL509499 0.72 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2KDM4EL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116940562-A Acetamido-phenylbenzamide derivatives and methods of use thereof 希华医药有限公司 2023-10-24 CN disclosed
EP-4225745-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME Athenex, Inc. (US) 2023-08-16 EP disclosed
WO-2022076662-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME ATHENEX, INC. (US) 2022-04-14 WO disclosed
US-20220106301-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME Health Hope Pharma Limited (HK) 2022-04-07 US disclosed
EP-0772594-A1 IMINOXYCARBOXYLATES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS Abbott Laboratories (US) 1997-05-14 EP disclosed
US-5512581-A ANTIINFLAMMATORY AGENT ABBOTT LABORATORIES (US) 1996-04-30 US disclosed
WO-1996002507-A1 IMINOXYCARBOXYLATES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS ABBOTT LABORATORIES (US) 1996-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106301-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME ABCB1, ABCC1, UGT2B7 ALDH1A1 102/4885SMN1; SMN2 3087/4885KDM4E 2232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.